Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs...

Area of Science:

• Cardiology
• Medical Devices
• Clinical Research

Background:

• Randomized clinical trials demonstrate the life-saving benefits of implantable cardioverter-defibrillator (ICD) therapy.
• It remains unclear if survival outcomes for patients receiving primary prevention ICDs in clinical practice mirror those observed in clinical trials.

Purpose of the Study:

• To compare the survival rates of patients who received a primary prevention ICD in a large national registry with those of similar patients in the MADIT-II and SCD-HeFT clinical trials.
• To assess the real-world effectiveness of primary prevention ICDs.

Main Methods:

• Retrospective analysis of the National Cardiovascular Data Registry ICD Registry (2006-2007) for patients meeting MADIT-II or SCD-HeFT criteria.
• Propensity score matching was used to create comparable cohorts.
• Cox proportional hazards models analyzed all-cause mortality.

Main Results:

• Registry patients were older with more comorbidities than trial participants.
• No significant survival difference was observed between registry and trial patients meeting MADIT-II criteria (2-year mortality: 13.9% vs. 15.6%).
• Similarly, survival was comparable for registry and trial patients meeting SCD-HeFT criteria (3-year mortality: 17.3% vs. 17.4%).

Conclusions:

• Survival outcomes for patients receiving primary prevention ICDs in clinical practice are comparable to those in major clinical trials.
• These findings validate the use of primary prevention ICDs in routine clinical care for eligible patients.
• The study supports the continued application of ICD therapy in real-world settings.